Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Lean MASLD (Phase 4, Double-Blind, Placebo-Controlled)
ChiCTR2600123421Phase 4Not yet recruiting
- Sponsor
- Central Hospital Affiliated to Shandong First Medical University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Metformin + lifestyle intervention with Placebo + lifestyle intervention (2 arms). Primary endpoint: Liver fat content. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2600123421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123421.